Verbalizing Extremes of the Visual Analogue Scale for Pruritus: A Consensus Statement

Furue, Masutaka; Ebata, Toshiya; Ikoma, Akihiko; Takeuchi, Satoshi; Kataoka, Yoko; Takamori, Kenji; Satoh, Takahiro; Saeki, Hidehisa; Augustin, Matthias; Reich, Adam; Szepietowski, Jacek C.; Fleischer, Alan B.; Blome, Christine; Phan, Ngoc Quan; Weißhaar, Elke; Yosipovitch, Gil; Ständer, Sonja

doi:10.2340/00015555-1446

Cited by 65 publications

(57 citation statements)

References 10 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study including patients with itchy dermatoses and patients with chronic pruritus of different aetiologies (a total of 781 European and Japanese patients) it was shown that data from VAS, NRS and VRS showed a high degree of reliability and correlation among each other (4)(5)(6). In a test-retest reliability analysis, a high degree of interclass correlation coefficients was found, confirming a good reproducibility of these instruments.…”

Section: Scales For Gathering Data On Pruritus Intensitysupporting

confidence: 61%

“…The VAS is a horizontal 10-cm long line, on which patients make a vertical mark to indicate their subjective assessment of pruritus intensity. The end-points are described as follows: 0 = no itch and 10 = the worst imaginable itch (6). The VAS is usually used as a horizontal line; however, there is also a vertical version of VAS, from which it differs only in small and non-significant ways (5).…”

Section: Scales For Gathering Data On Pruritus Intensitymentioning

confidence: 99%

See 1 more Smart Citation

Pruritus Assessment in Clinical Trials: Consensus Recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials

Ständer¹,

Augustin²,

Reich³

et al. 2013

Acta Derm Venerol

Self Cite

165

176

View full text Add to dashboard Cite

Chronic pruritus is a common symptom and there is an urgent need to test new anti-pruritic substances in high-quality clinical trials. However, no widely accepted standardized and validated method for objectively measuring pruritus is yet available. A special interest group of the International Forum for the Study of Itch has been established to assess scoring methods and questionnaires for use in clinical trials. This paper presents our current recommendations. The set of measures we recommend includes pruritus intensity scales, instruments for assessment of scratch lesions, chronic pruritus course, quality of life and patient benefits.

show abstract

Section: Scales For Gathering Data On Pruritus Intensitysupporting

confidence: 61%

Section: Scales For Gathering Data On Pruritus Intensitymentioning

confidence: 99%

Pruritus Assessment in Clinical Trials: Consensus Recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials

Ständer¹,

Augustin²,

Reich³

et al. 2013

Acta Derm Venerol

Self Cite

165

176

View full text Add to dashboard Cite

show abstract

“…The scales used for assessing itchiness include the visual analog scale (VAS) [9][10][11][12], numerical rating scale (NRS) [10][11][12], and verbal rating scale (VRS) [10][11][12]. VAS and the Shiratori severity score for pruritus (Shiratori score) [13], divided into a type of VRS, and the Kawashima classification [14], a simplified version of the Shiratori score, are commonly used in Japan.…”

Section: Introductionmentioning

confidence: 99%

Usefulness of the Japanese version of the 5-D itch scale for rating pruritus experienced by patients undergoing hemodialysis

et al. 2018

View full text Add to dashboard Cite

Background: Pruritus in patients undergoing hemodialysis reduces quality of life via insomnia and depression, and negatively affects prognosis. For diagnosing pruritus, selecting therapeutic strategies, and determining therapeutic outcomes, methods are needed for objectively quantifying the degree of itchiness. In 2015, the Japanese version of the 5-D itch scale (5D-J), originally developed in the USA in 2010, was developed as a simple self-administered questionnaire; it evaluated the degree of itchiness based on five components: (1) duration of itchiness, (2) degree of itchiness, (3) direction of itchiness, (4) disability caused by itchiness, and (5) distribution of itchiness. 5D-J is useful for comprehensively assessing multiple elements related to itchiness. We used 5D-J to assess the degree of itchiness experienced by patients undergoing hemodialysis to investigate its clinical usefulness. Methods: Subjects were 336 patients undergoing maintenance hemodialysis at our facility in October 2016; they were selected from 383 patients, of whom 20 were excluded because their itchiness had a dermatologic origin and 27 were excluded because their localized itchiness was related to vascular access, respectively. The status of itchiness (duration, degree, direction, disability, and distribution) of the patients was surveyed in October 2016 using 5D-J; total scores were calculated and used for assessing the itchiness experienced by patients. We additionally investigated whether 5D-J scores correlated with visual analog scale (VAS) and Shiratori severity scores for pruritus. Results: Degree was reported as "not present" by 124 patients (36.9%), "mild" by 164 (48.8%), "moderate" by 46 (13.7%), "severe" by 2 (0.6%), and "unbearable" by 0 (0%). Total score was 5 points in 55 patients (16.4%), 6-9 in 176 (52.4%), 10-14 in 95 (28.3%), 15-19 in 9 (2.7%), 20-24 in 1 (0.3%), and 25 in 0 (0%). The 5D-J total and VAS scores were strongly correlated (r = 0.7159; p < 0.001). The 5D-J total score correlated with "daytime itchiness" (r = 0.6441; p < 0.001) and "nighttime itchiness" (r = 0.6352; p < 0.001) on the Shiratori severity score. Conclusions: 5D-J may be useful for objectively assessing itchiness experienced by patients undergoing hemodialysis.

show abstract

“…[18][19][20][21][22][23] One may consider adapting them for use in Figure 3 High-frequency ultrasound of skin…”

Section: Assessment Of Tumor Number and Sizementioning

confidence: 99%

Clinical trial design for cutaneous neurofibromas

et al. 2018

View full text Add to dashboard Cite

Objective Several clinical trials targeting cutaneous neurofibromas (cNF) have been conducted; however, none has resulted in meaningful changes to care. The Clinical Trial Design and Development subgroup's goals were to (1) define key considerations in the design of clinical trials for cNF, (2) summarize existing data in relation to these considerations, and (3) provide consensus recommendations about key elements of trial design to accelerate the clinical development of therapies for cNF. MethodsThe subgroup, with experts from genetics, dermatology, neurology, oncology, and basic science, spanning academia, government research, and regulatory programs, and industry, reviewed published and unpublished data on clinical trials for cNF and other diseases in the skin. Discussions of these data resulted in formulation of a list of priority issues to address in order to develop efficient and effective clinical trials for cNF.

show abstract

Verbalizing Extremes of the Visual Analogue Scale for Pruritus: A Consensus Statement

Cited by 65 publications

References 10 publications

Pruritus Assessment in Clinical Trials: Consensus Recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials

Pruritus Assessment in Clinical Trials: Consensus Recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials

Usefulness of the Japanese version of the 5-D itch scale for rating pruritus experienced by patients undergoing hemodialysis

Clinical trial design for cutaneous neurofibromas

Contact Info

Product

Resources

About